Stockscreener 앱 받기
21.38
0.52%
0.11
시간 외 거래:
21.45
0.07
+0.33%
전일 마감가:
$21.27
열려 있는:
$21.27
하루 거래량:
831.24K
Relative Volume:
1.30
시가총액:
$960.66M
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
14.74
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
-1.66%
1개월 성능:
-17.04%
6개월 성능:
-20.52%
1년 성능:
+28.80%
1일 변동 폭
$20.96
$21.77
1주일 범위
$20.50
$21.85
52주 변동 폭
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.38 | 955.72M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Why Pacira BioSciences Inc. (82P) stock could outperform next yearJuly 2025 Volume & Community Consensus Picks - newser.com
Pacira BioSciences Inc. recovery potential after sell off2025 Market Overview & Community Consensus Stock Picks - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Building trade automation scripts for Pacira BioSciences Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Is Pacira BioSciences Inc. stock poised for growthBuy Signal & Free Accurate Trade Setup Notifications - newser.com
Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Update & Fast Exit Strategy with Risk Control - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Pacira BioSciences Inc. stock retracement – recovery analysis2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo
Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Pacira BioSciences (Nasdaq: PCRX) sets Nov. 6 third-quarter results; call at 4:30 p.m. ET - Stock Titan
Will Pacira BioSciences Inc. stock keep outperforming rivalsMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Market Trend Review & Weekly Momentum Stock Picks - newser.com
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-To-Severe Osteoarthritis of the Knee - MarketScreener
Pacira BioSciences (PCRX) Reports Promising Three-Year Findings for PCRX-201 - GuruFocus
Is Pacira BioSciences Inc. stock a buy on dipsForecast Cut & Smart Investment Allocation Insights - Fundação Cultural do Pará
Pacira Biosciences Increceives Paragraph IV notice from Qilu Pharmaceutical - MarketScreener
Pacira BioSciences receives patent challenge for EXPAREL from Chinese firm - Investing.com
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - The Manila Times
Pacira BioSciences Receives PIV Notice from Qilu Pharmaceutical Regarding Generic EXPAREL Patent Claims - Quiver Quantitative
Pacira BioSciences (NASDAQ: PCRX) notes PIV ANDA for EXPAREL; 45 days to file suit - Stock Titan
How Pacira BioSciences Inc. stock trades before earnings2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.18%
1.86%
자본화:
|
볼륨(24시간):